Protalix BioTherapeutics

PLX59

Penny Stock

$1.69arrow_drop_up2.40%$0.04

Penny Stock

PLX59

$1.69

arrow_drop_up2.40%$0.04

Penny Stock

Performance History

Key Stats
Open	$1.68
Prev. Close	$1.66
EPS	-0.15
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$124.44M
PE Ratio	-

	LOW	HIGH
Day Range	1.66	1.76
52 Week Range	0.82	1.90

Ratios







EPS	-0.15

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Protalix BioTherapeutics (PLX)

Protalix BioTherapeutics Inc (PLX) is a biopharmaceutical company that focuses on the development and commercialization of recombinant therapeutic proteins. The company's primary product, taliglucerase alfa, is an enzyme replacement therapy used for the treatment of Gaucher disease. Gaucher disease is a rare genetic disorder that affects the body's ability to break down certain types of fat. Taliglucerase alfa is a plant cell-based treatment that offers several advantages over traditional enzyme replacement therapies, including increased production capacity and reduced risk of contamination.

PLX stock has a volatile price history, with significant fluctuations over the years. The stock reached its highest point in 2012, with a price of $8.55 per share. However, it has since experienced periods of decline and recovery. As of the most recent trading session, PLX stock was trading at $3.23 per share.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Dror Bashan
Headquarters: Hackensack
Employees: 193
Exchange: NYSE

add Protalix BioTherapeutics to watchlist

Keep an eye on Protalix BioTherapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Protalix BioTherapeutics 's (PLX) price per share?

The current price per share for Protalix BioTherapeutics (PLX) is $1.69. The stock has seen a price change of $0.04 recently, indicating a 2.41% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Protalix BioTherapeutics (PLX)?

For Protalix BioTherapeutics (PLX), the 52-week high is $1.9, which is 12.43% from the current price. The 52-week low is $0.82, the current price is 106.1% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Protalix BioTherapeutics (PLX) a growth stock?

Protalix BioTherapeutics (PLX) has shown an average price growth of -4.13% over the past three years. It has received a score of 75 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Protalix BioTherapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Protalix BioTherapeutics (PLX) stock price performance year to date (YTD)?

As of the latest data, Protalix BioTherapeutics (PLX) has a year-to-date price change of -7.14%. Over the past month, the stock has experienced a price change of 59.43%. Over the last three months, the change has been 80.07%. Over the past six months, the figure is 31.01%. Looking at a longer horizon, the five-year price change stands at -32.75%.

help

Is Protalix BioTherapeutics (PLX) a profitable company?

Protalix BioTherapeutics (PLX) has a net income of $8.31M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 64.91% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -18.01% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $65.49M, with a revenue growth rate of 37.48%, providing insight into the company's sales performance and growth. The gross profit is $42.51M. Operating income is noted at $10.46M. Furthermore, the EBITDA is $12.94M.

help

What is the market capitalization of Protalix BioTherapeutics (PLX)?

Protalix BioTherapeutics (PLX) has a market capitalization of $124.44M. The average daily trading volume is 1.7, indicating the stock's liquidity and investor engagement.